ADDvise Group’s order intake reached SEK 524.0 million in Q4 2022, an increase of 195.0 %

11-01-2023   Regulatory press release

ADDvise Group’s order intake during the fourth quarter of 2022 amounted to SEK 524.0 million, an increase of 195.0 percent on the same period for the previous year. Order intake in the same quarter of the previous year amounted to SEK 177.6 million. 7.7 percent of the increase in order intake was organic. Order intake for the full year 2022 amounted to SEK 1184.1 million, an increase of 134.5 compared to 2021 when the figure was SEK 505.0 million. The organic increase in order intake for the full year 2022 was 9.6 percent.

“The backend of 2022 was strong, and we’re continuing to see a high level of activity in most of our businesses. This is particularly true of the US market, which now accounts for more than half of the Group’s revenue,” says CEO Rikard Akhtarzand, commenting on the order figures.

ADDvise Group’s Year-End Report is published February 23, 2023.

For further information, please contact:

Rikard Akhtarzand, CEO
+46 (0)765-25 90 71
rikard.akhtarzand@addvisegroup.se


Important information:

This information is information that ADDvise Group AB is required to disclose under the EU Market Abuse Regulation. The information was released for publication on January 11, 2023 at 16:15 CET.

 

About ADDvise Group

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The Group consists of two business units: Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expanding the business—both geographically and product-wise. ADDvise Group’s shares are listed on Nasdaq First North Premier Growth Market, and Mangold Fondkommission AB, +46 (0)8-503 015 50, CA@mangold.se, is the company’s certified adviser. Further information is available at www.addvisegroup.com.              

Latest press releases

ADDvise announces preliminary result for 2022 which is stronger than expected

Regulatory

The preliminary result for ADDvise Group for the full year 2022 significantly deviates from what ADDvise Group considers to be current market expectations. [image] The net sales pro forma full year 2022 rolling 12 months amounted to SEK 1,097 million with an adjusted EBITDA pro forma of SEK 241 million. The financial targets for the…

ADDvise receives order worth USD 3.5 million

Regulatory

ADDvise Group AB’s subsidiary Poly Pharmaceuticals Inc has received an order from AxisCare Health Logistics Inc, a company distributing equipment and medical supplies to hospitals, clinics, medical offices and medical equipment suppliers. The order is worth approximately USD 3.5 million. The order consists of delivery of the prescription dietary supplemental Folite, developed and manufactured by…

ADDvise receives order worth USD 1.8 million

Regulatory

ADDvise Group AB’s subsidiary MRC Systems FZE has received an order from Nasser Saeed Al Hajri & Partners Contracting (NHS & Partners), a leading construction contractor in the United Arab Emirates. The order is worth approximately USD 1.8 million. The order involves the detailed design, supply and installation of an ISO 8 and ISO 7…